Sylvaine You1, Lucienne Chatenoud. 1. aUniversité Paris Descartes, France bINSERM, Unité 1013, Paris, France *Sylvaine You and Lucienne Chatenoud contribute equally to the writing of this article.
Abstract
PURPOSE OF REVIEW: The continuing problem of late graft loss and immunosuppressive drug toxicity forces us to explore new treatments for the induction of transplant tolerance. Monoclonal antibodies targeting molecules implicated in lymphocyte activation, in particular CD3/TCR, constitute a promising strategy. RECENT FINDINGS: Promising results were obtained from the use of antibodies targeting CD3/TCR, coreceptors or costimulatory pathways as tolerance-promoting tools in experimental transplantation. These antibodies do not uniformly depress the immune system but act in an antigen-specific manner by preferentially targeting effector T cells while preserving regulatory T cells. However, translation to the clinic proved to be more difficult than expected. New generation CD3 antibodies, currently used in phase II/III trials in autoimmunity, constitute a promising approach as, beside their immunosuppressive effect, they also express potent tolerogenic capacities. Importantly, CD3 therapy is effective especially when applied in primed hosts, highlighting the importance of the therapeutic window for tolerance induction. SUMMARY: Further investigations are required for adapting to the clinic monoclonal antibodies as substitutes for current immunosuppression. Our aim is to show that development of new therapeutic strategies/molecules may come from transversal-type research, in particular from experience in autoimmunity, as immune responses leading to autoimmunity and graft rejection involve similar pathways.
PURPOSE OF REVIEW: The continuing problem of late graft loss and immunosuppressive drug toxicity forces us to explore new treatments for the induction of transplant tolerance. Monoclonal antibodies targeting molecules implicated in lymphocyte activation, in particular CD3/TCR, constitute a promising strategy. RECENT FINDINGS: Promising results were obtained from the use of antibodies targeting CD3/TCR, coreceptors or costimulatory pathways as tolerance-promoting tools in experimental transplantation. These antibodies do not uniformly depress the immune system but act in an antigen-specific manner by preferentially targeting effector T cells while preserving regulatory T cells. However, translation to the clinic proved to be more difficult than expected. New generation CD3 antibodies, currently used in phase II/III trials in autoimmunity, constitute a promising approach as, beside their immunosuppressive effect, they also express potent tolerogenic capacities. Importantly, CD3 therapy is effective especially when applied in primed hosts, highlighting the importance of the therapeutic window for tolerance induction. SUMMARY: Further investigations are required for adapting to the clinic monoclonal antibodies as substitutes for current immunosuppression. Our aim is to show that development of new therapeutic strategies/molecules may come from transversal-type research, in particular from experience in autoimmunity, as immune responses leading to autoimmunity and graft rejection involve similar pathways.
Authors: Veronica Marrella; Pietro L Poliani; Elena Fontana; Anna Casati; Virginia Maina; Barbara Cassani; Francesca Ficara; Manuela Cominelli; Francesca Schena; Marianna Paulis; Elisabetta Traggiai; Paolo Vezzoni; Fabio Grassi; Anna Villa Journal: Blood Date: 2012-06-21 Impact factor: 22.113
Authors: Y Miyahara; M Khattar; P M Schroder; B Mierzejewska; R Deng; R Han; W W Hancock; W Chen; S M Stepkowski Journal: Am J Transplant Date: 2012-03-15 Impact factor: 8.086
Authors: M Segovia; C Louvet; P Charnet; A Savina; G Tilly; L Gautreau; L Carretero-Iglesia; G Beriou; I Cebrian; T Cens; L Hepburn; E Chiffoleau; R A Floto; I Anegon; S Amigorena; M Hill; M C Cuturi Journal: Am J Transplant Date: 2014-04-14 Impact factor: 8.086